PE20220570A1 - Anticuerpo anti-epha4 humano - Google Patents
Anticuerpo anti-epha4 humanoInfo
- Publication number
- PE20220570A1 PE20220570A1 PE2021002077A PE2021002077A PE20220570A1 PE 20220570 A1 PE20220570 A1 PE 20220570A1 PE 2021002077 A PE2021002077 A PE 2021002077A PE 2021002077 A PE2021002077 A PE 2021002077A PE 20220570 A1 PE20220570 A1 PE 20220570A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- human anti
- heavy chain
- Prior art date
Links
- 150000001413 amino acids Chemical group 0.000 abstract 6
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UN ANTICUERPO QUE SE UNE A EphA4 QUE COMPRENDE CADENAS PESADA Y LIGERA, LAS CUALES COMPRENDEN: A) UNA CDR1 DE CADENA PESADA QUE CONSISTE EN LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 44, B) UNA CDR2 DE CADENA PESADA QUE CONSISTE EN LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 27, C) UNA CDR3 DE CADENA PESADA QUE CONSISTE EN LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 28, D) UNA CDR1 DE CADENA LIGERA QUE CONSISTE EN LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 29, E) UNA CDR2 DE CADENA LIGERA QUE CONSISTE EN LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 30, Y F) UNA CDR3 DE CADENA LIGERA QUE CONSISTE EN LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 31. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019122982 | 2019-07-01 | ||
| PCT/JP2020/025465 WO2021002312A1 (ja) | 2019-07-01 | 2020-06-29 | 抗ＥｐｈＡ４抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220570A1 true PE20220570A1 (es) | 2022-04-20 |
Family
ID=74066003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021002077A PE20220570A1 (es) | 2019-07-01 | 2020-06-29 | Anticuerpo anti-epha4 humano |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10947313B2 (es) |
| EP (1) | EP3995582A4 (es) |
| JP (2) | JP6979147B2 (es) |
| KR (1) | KR20220027825A (es) |
| CN (2) | CN113906050B (es) |
| AR (1) | AR119303A1 (es) |
| AU (1) | AU2020300205A1 (es) |
| BR (1) | BR112021025161A2 (es) |
| CA (1) | CA3139398A1 (es) |
| CL (1) | CL2021003326A1 (es) |
| CO (1) | CO2021016588A2 (es) |
| IL (1) | IL287828A (es) |
| JO (1) | JOP20210333A1 (es) |
| MA (1) | MA56466A (es) |
| MX (1) | MX2021015298A (es) |
| PE (1) | PE20220570A1 (es) |
| PH (1) | PH12021553090A1 (es) |
| SG (1) | SG11202112433VA (es) |
| TW (3) | TWI866304B (es) |
| WO (1) | WO2021002312A1 (es) |
| ZA (1) | ZA202108836B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| TWI866304B (zh) | 2019-07-01 | 2024-12-11 | 日商衛材R&D企管股份有限公司 | 抗EphA4抗體 |
| JPWO2022138707A1 (es) * | 2020-12-24 | 2022-06-30 | ||
| TW202323286A (zh) * | 2021-11-11 | 2023-06-16 | 日商衛材R&D企管股份有限公司 | 抗EphA4抗體 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1094731A (en) | 1911-06-06 | 1914-04-28 | Lucien Linden | Oxidizing process. |
| JP2824433B2 (ja) | 1988-12-09 | 1998-11-11 | 財団法人化学及血清療法研究所 | 新規なハイブリッドプロモーターおよびこれを組み込んだ外来遺伝子発現用ベクター |
| AU629554B2 (en) | 1988-06-24 | 1992-10-08 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Exogenous gene expression vector containing chick beta-actin gene promoter |
| JP3680114B2 (ja) | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
| US5902732A (en) | 1995-10-04 | 1999-05-11 | Cytoscan Sciences Llc | Drug screening process measuring changes in cell volume |
| AU6887698A (en) | 1997-04-08 | 1998-10-30 | Sugen, Inc. | Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases |
| US20020068361A1 (en) | 1997-04-08 | 2002-06-06 | Douglas Clary | Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner |
| US5876946A (en) | 1997-06-03 | 1999-03-02 | Pharmacopeia, Inc. | High-throughput assay |
| WO2003016475A2 (en) | 2001-08-14 | 2003-02-27 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| US20070026409A1 (en) | 2001-08-14 | 2007-02-01 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| US20060241074A1 (en) | 2001-08-14 | 2006-10-26 | The General Hospital Corporation | Methods for treatment of pain |
| JP2003169699A (ja) | 2001-12-10 | 2003-06-17 | Japan Science & Technology Corp | 特異的γプロテアーゼ阻害剤のスクリーニング方法 |
| JP2004000060A (ja) | 2002-05-31 | 2004-01-08 | Otsuka Pharmaceut Co Ltd | アミロイドβ産生に影響を与える化合物のスクリーニング方法 |
| US8461119B2 (en) | 2002-09-24 | 2013-06-11 | The Burnham Institute | Agents that modulate Eph receptor activity |
| CN1717485A (zh) | 2002-11-26 | 2006-01-04 | 法玛西雅厄普约翰有限责任公司 | γ分泌酶的可溶性NOTCH－型底物和使用所述底物的方法和组合物 |
| EP1638514A4 (en) | 2003-06-06 | 2009-11-18 | Medimmune Inc | USE OF EPHA4 AND MODULATOR OR EPHA4 FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER |
| CN1878865A (zh) | 2003-11-10 | 2006-12-13 | 财团法人大阪产业振兴机构 | 无细胞Notch切割分析方法以及药物筛选方法 |
| TW200538739A (en) | 2004-02-27 | 2005-12-01 | Oncotherapy Science Inc | EphA4 as therapeutic target of PRC and PDACa |
| NZ553273A (en) | 2004-09-08 | 2009-11-27 | Univ Melbourne | Treating gliosis, glial scarring, inflammation or inhibition of a xonal growth in the nervous system with an antagonist of EphA4-mediated signalling |
| EP1662259A1 (en) | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
| GB0427023D0 (en) | 2004-12-09 | 2005-01-12 | Merck Sharp & Dohme | Assay method |
| CN101432022A (zh) | 2006-02-28 | 2009-05-13 | 肿瘤疗法科学股份有限公司 | 利用抗-EphA4抗体效应物作用损伤细胞的方法 |
| EP1947193A1 (en) | 2007-01-17 | 2008-07-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Screening method for anti-diabetic compounds |
| WO2008150010A1 (ja) | 2007-06-08 | 2008-12-11 | Eisai R & D Management Co., Ltd. | γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法 |
| US20090023158A1 (en) | 2007-07-13 | 2009-01-22 | Elan Pharmaceuticals, Inc. | Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase |
| US20090191580A1 (en) | 2007-07-19 | 2009-07-30 | Eisai R & D Management Co., Ltd. | METHOD OF SCREENING USING c-MET, A NOVEL SUBSTRATE FOR GAMMA-SECRETASE |
| EP2192181A4 (en) | 2007-08-01 | 2010-12-08 | Eisai R&D Man Co Ltd | SCREENING METHOD USING THE NEW C-RET SUBSTRATE FOR GAMMA-SECRETASE |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| US20090163594A1 (en) | 2007-10-31 | 2009-06-25 | Elan Pharmaceuticals, Inc. | Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors |
| EP2219028B1 (en) | 2007-11-15 | 2012-09-12 | Eisai R&D Management Co., Ltd. | Screening method utilizing novel substrate epha7 for gamma-secretase |
| EP2223999B1 (en) | 2007-11-30 | 2017-10-18 | Eisai R&D Management Co., Ltd. | Epha4 polypeptide having novel activity and use thereof |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| EP2260864A1 (en) | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
| JP2010285413A (ja) | 2009-06-10 | 2010-12-24 | Univ Of Melbourne | 治療用途 |
| EP2653552B1 (en) | 2010-12-17 | 2016-10-19 | Eisai R&D Management Co., Ltd. | SCREENING METHOD USING GELATINASE-MEDIATED EphA4 CLEAVAGE REACTION AS AN INDICATOR |
| JP5961608B2 (ja) | 2011-04-25 | 2016-08-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法 |
| GB201107996D0 (en) | 2011-05-13 | 2011-06-29 | Vib Vzw | EphA4 is a diease modifier in motor neuron disease |
| ES2925224T3 (es) | 2014-07-31 | 2022-10-14 | Us Gov Health & Human Services | Anticuerpos monoclonales humanos contra EphA4 y su uso |
| CA2989993A1 (en) * | 2015-09-08 | 2017-03-16 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| TWI866304B (zh) | 2019-07-01 | 2024-12-11 | 日商衛材R&D企管股份有限公司 | 抗EphA4抗體 |
-
2020
- 2020-06-29 TW TW112123862A patent/TWI866304B/zh active
- 2020-06-29 TW TW111133484A patent/TWI808882B/zh active
- 2020-06-29 TW TW109121908A patent/TWI779307B/zh active
- 2020-06-29 CN CN202080039114.0A patent/CN113906050B/zh active Active
- 2020-06-29 MA MA056466A patent/MA56466A/fr unknown
- 2020-06-29 EP EP20834769.0A patent/EP3995582A4/en active Pending
- 2020-06-29 JO JOP/2021/0333A patent/JOP20210333A1/ar unknown
- 2020-06-29 KR KR1020217038552A patent/KR20220027825A/ko active Pending
- 2020-06-29 CA CA3139398A patent/CA3139398A1/en active Pending
- 2020-06-29 AU AU2020300205A patent/AU2020300205A1/en active Pending
- 2020-06-29 BR BR112021025161A patent/BR112021025161A2/pt unknown
- 2020-06-29 WO PCT/JP2020/025465 patent/WO2021002312A1/ja active Application Filing
- 2020-06-29 PE PE2021002077A patent/PE20220570A1/es unknown
- 2020-06-29 CN CN202311449611.XA patent/CN117398459A/zh active Pending
- 2020-06-29 PH PH1/2021/553090A patent/PH12021553090A1/en unknown
- 2020-06-29 AR ARP200101834A patent/AR119303A1/es unknown
- 2020-06-29 US US16/915,412 patent/US10947313B2/en active Active
- 2020-06-29 SG SG11202112433VA patent/SG11202112433VA/en unknown
- 2020-06-29 JP JP2021519890A patent/JP6979147B2/ja active Active
- 2020-06-29 MX MX2021015298A patent/MX2021015298A/es unknown
-
2021
- 2021-01-08 US US17/145,001 patent/US11136400B2/en active Active
- 2021-11-03 IL IL287828A patent/IL287828A/en unknown
- 2021-11-09 ZA ZA2021/08836A patent/ZA202108836B/en unknown
- 2021-11-12 JP JP2021184594A patent/JP7072114B2/ja active Active
- 2021-12-07 CO CONC2021/0016588A patent/CO2021016588A2/es unknown
- 2021-12-13 CL CL2021003326A patent/CL2021003326A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220570A1 (es) | Anticuerpo anti-epha4 humano | |
| RU2505603C2 (ru) | Антитело против рецептора il-6 | |
| PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20120429A1 (es) | Proteinas de enlace de miostatina | |
| AR071510A1 (es) | Anticuerpos anti- factor d humanizados y sus usos | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| PE20120306A1 (es) | Anticuerpos anti-egfr y vectores que los codifican | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| PE20110797A1 (es) | Anticuerpos anti mn | |
| AR117911A2 (es) | Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| PE20120816A1 (es) | Composiciones que comprenden anticuerpos de dickkopf-1 | |
| PE20190975A1 (es) | Novela cd47 anticuerpos monoclonales y sus usos | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| PE20161390A1 (es) | Anticuerpos multiespecificos | |
| PE20110802A1 (es) | Un anticuerpo antagonista de pcsk9 | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| PE20130393A1 (es) | Anticuerpos con union de antigenos dependiente de ph | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| PE20170912A1 (es) | Conjugados de anticuerpo-farmaco | |
| PE20180499A1 (es) | Anticuerpos de union a tau | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| PE20221263A1 (es) | Agentes de union a ilt3 y metodos de uso de los mismos | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |